FDA Review Of Novartis' Entresto Shows Agency's Practical Side
Executive Summary
Pivotal trial of Novartis' sacubitril/valsartan duo in heart failure did not conform to FDA's combination policy, but agency ultimately valued its mortality effect over statistical correctness.
You may also be interested in...
Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval
Reimbursement complexity and physician reluctance to move stable patients off their current treatment regimens are the biggest hurdles.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.